- Conditions
- Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Enzalutamide, Niclosamide
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
Condition Directory
Prostate Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 10, 2026 Report an issue
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
3919
Shown on this page
12
Current sort
Recently updated
Condition scope
Prostate Cancer
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Prostate Cancer studies are organized in the registry
Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 889–900 of 3,919 matching trials for Prostate Cancer.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Prostate Cancer (Adenocarcinoma), Bladder Cancer, Kidney Cancers, Testis Cancer
- Interventions
- Pub2Post
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
- Drug
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Stanford, California • River Ridge, Louisiana • Grand Rapids, Michigan + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
- Drug · Radiation
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 19
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- REGN4336, REGN5678
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 13
- States / cities
- Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more
- Conditions
- Early Stage Prostate Cancer
- Interventions
- Hypofractionated Radiation
- Radiation
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Standard Salvage Radiation Treatment (SSRT), Mapped Tumor Salvage RT (MTSRT)
- Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 35 Years to 85 Years · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Breast Cancer, Lung Cancer, Pancreas Cancer, Prostate Cancer
- Interventions
- axelopran
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Saint Louis Park, Minnesota • Saint Paul, Minnesota
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
- Combination Product · Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Enzalutamide, Ruxolitinib
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan
- Conditions
- Prostate Carcinoma
- Interventions
- Biopsy, Endorectal Magnetic Resonance Imaging
- Device · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Castrate Sensitive Prostate Cancer, Metastatic Prostate Cancer
- Interventions
- Home-Based Exercise Intervention - Walking, Home-Based Exercise Intervention - HIIT Cycling
- Behavioral
- Lead sponsor
- Paul Viscuse
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
About this Prostate Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Prostate Cancer.